Company intelligence / Profile preview

Praxis Precision Medicines

Cambridge, Massachusetts, United Statespraxismedicines.com ↗

Ownership: Public · PRAX
Development stage: Phase 2

Overview

Praxis has reported positive topline results from a Phase II trial of vormatrigine in epilepsy, robust efficacy for relutrigine in DEEs, and expects pivotal readouts for ulixacaltamide in essential tremor as well as further data on elsunersen for SCN2A-DEE. Four product launches are targeted between 2026–2028 if trials succeed.

Therapeutic areas: Neurology
Modalities: Small moleculeAntisense oligonucleotide
Industry: Biotech

Drug pipeline

13 assets

PRAX-114

12 more assets in the full pipeline.

Request access →

Partnerships

UCB licensed global rights to a KCNT1 small-molecule program from Praxis with up to $100M in milestones plus royalties.

Financials

Market cap: $9.6B
Total revenue: $0
Enterprise value: $8.9B

Beyond the preview

Go deeper on Praxis Precision Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Praxis Precision Medicines.

Explore the full profile